Ludmil Alexandrov, PhD, on Use of AI to Predict HRD and Response Directly From Routine Biopsy Slides
A novel artificial intelligence (AI) protocol called DeepHRD was able to predict homologous recombination deficiency (HRD) in ovarian and breast cancers directly from routine histopathological slides.
Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback